Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with ... Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -6.69 | -13.2869910626 | 50.35 | 50.35 | 38.5 | 10053 | 39.79178924 | CS |
| 4 | -5.24 | -10.7157464213 | 48.9 | 50.82 | 38.5 | 3340 | 40.68821147 | CS |
| 12 | -0.28 | -0.637232589895 | 43.94 | 55.36 | 38.5 | 2494 | 44.007929 | CS |
| 26 | -36.14 | -45.2882205514 | 79.8 | 79.86 | 35.931 | 3310 | 49.379515 | CS |
| 52 | -31.25 | -41.7167267388 | 74.91 | 83.12 | 35.931 | 1915 | 52.21104154 | CS |
| 156 | 3.66 | 9.15 | 40 | 141.742 | 33.42 | 1645 | 82.22039165 | CS |
| 260 | 11.96 | 37.7287066246 | 31.7 | 141.742 | 11.14 | 1489 | 78.40955475 | CS |
Trading2retire
10年前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。